Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 open-label study of intratumoral mRNA-2416 alone or with durvalumab in advanced malignancies, including ovarian cancer expansion
MOH_2020-10-12_009386Phase 2Completed
- Sponsor
- Moderna Inc
- Start
- Sep 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of mRNA-2416 and durvalumab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC) and 1 more (2 arms), sponsored by Moderna Inc. Primary endpoint: Objective response rate. Started Sep 2020; status: completed.
02
Drugs
mRNA-2416durvalumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)advanced cancer
Beyond the preview
Go deeper on MOH_2020-10-12_009386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-10-12_009386.